Latigo Biotherapeutics is appointing Neha Krishnamohan as both Chief Financial Officer (CFO) and Chief Business Officer (CBO).

Latigo is a clinical-stage biopharmaceutical company that innovates to develop non-opioid pain medicines.

Krishnamohan Responds to Appointment

In comments in a press release, Krishnamohan emphasized Latigo’s mission—to stop pain transmission without risk of addiction.

“I am honored and energized to join the team at Latigo at a pivotal time for the company,” Krishnamohan said. She added she looks forward to contributing to Latigo’s next phase of growth.

“Latigo has the potential to transform pain management with a differentiated pipeline of non-opioid pain programs,” she continued. “I look forward to partnering with Latigo’s talented management team and board to advance Latigo’s strategic and financial objectives.”

It is a board of directors with which Krishnamohan is well familiar; she most recently was its audit committee chair.

Advancements for Latigo Biotherapeutics

Latigo CEO Nima Farzan elaborated on the differentiated pipeline the company is advancing.

Farzan said it has “potential to meaningfully improve patient outcomes while simultaneously addressing the devastating societal problem of opioid addiction.”

The CEO extolled Krishnamohan’s “financial stewardship, strategic insight, and experience across corporate strategy, business development, [and] capital markets.”

Farzan—who became CEO in July 2024—said Krishnamohan also has experience “leading companies through high-impact corporate milestones.”

Before coming to Latigo, Krishnamohan was CFO and executive vice president (EVP) of corporate development at Artiva Biotherapeutics. Prior to that, she was CFO and EVP of corporate development at Kinnate Biopharma. She was also previously a vice president at Goldman Sachs.

In addition to having been on Latigo’s board, Krishnamohan is currently on the board of Arcutis Therapeutics.